Skip to main content
. 2022 Mar 28;60(5):54. doi: 10.3892/ijo.2022.5344

Figure 1.

Figure 1

Ricolinostat enhances adavosertib-induced cytotoxicity in HNSCC cell lines. CAL27, UPCI-SCC-154, HSC-3, SAS, MDA-MB-231, and A549 cells were treated with Adv in combination with RCS for up to 48 h. Cells were monitored using IncuCyte live cell imaging system, and dead cell number was assessed using PI staining. Time-dependent and dose-dependent cell death numbers are shown in the left and the middle panels, respectively. Representative data of three independent experiments are shown. n=3, bar, mean ± SD. Synergistically enhanced cell death in the combination treatment was analyzed as described in Materials and methods and summarized in the right panels. A significant synergistic effect with both Adv and RCS treatment with P<0.05 is shown in red. An antagonistic effect with P<0.05 is shown in blue. HNSCC, head and neck squamous cell carcinoma; Adv, adavosertib; RCS, ricolinostat.